<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906683</url>
  </required_header>
  <id_info>
    <org_study_id>10060050</org_study_id>
    <nct_id>NCT02906683</nct_id>
  </id_info>
  <brief_title>Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence</brief_title>
  <official_title>A Phase IIa Study of TAS-303 in Female Patients With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female
      patients with stress urinary incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to assess the efficacy of TAS-303 for 8 weeks in female
      patients with stress urinary incontinence (SUI) compared with placebo as measured by the
      percent change in incontinence episode frequency (IEF) from baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change in incontinence episode frequency</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the incontinence episode frequency</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the incontinence amount in 1-hour pad weight test</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the international Consultation on Incontinence Questionnaire-Short Form(ICIQ-SF)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the Patient's Global Impressions of Improvement (PGI I) questionnaire.</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the incontinence quality of life instrument (I QOL) scores</measure>
    <time_frame>Baseline and 4 and 8 weeks after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence and severity of adverse events</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>TAS-303 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-303 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-303</intervention_name>
    <description>Oral administration for 8 weeks, once daily.</description>
    <arm_group_label>TAS-303 3mg</arm_group_label>
    <arm_group_label>TAS-303 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration for 8 weeks, once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior
             to study entry

          -  Patient has at least 1 incontinence episodes per day, and urinary diurnal frequency of
             10 or less per day and nocturia of 2 or less per day.

          -  Patient is positive in 1-hour pad weight test

        Exclusion Criteria:

          -  Patient has predominant or primary urge incontinence according to investigator
             judgment

          -  Patient had a prior surgical SUI treatment

          -  Patient is diagnosed stageII or more of Pelvic Organ Prolapse

          -  Patient has symptoms of Urinary tract infection (UTI)

          -  Patient is positive pregnancy test

          -  Patient has on physical examination, neurological and/or vaginal examination results
             which, in the opinion of the investigator, should exclude the subject.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <email>toiawase@taiho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taiho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Urinary Incontinence, Stress</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

